Last reviewed · How we verify
Pantogar
At a glance
| Generic name | Pantogar |
|---|---|
| Sponsor | EMS |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women. (PHASE3)
- Efficacy and Safety of Neosil on Chronic Effluvium (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pantogar CI brief — competitive landscape report
- Pantogar updates RSS · CI watch RSS
- EMS portfolio CI